Table 2

Recommendation 1: summary of studies on the use of MRI in diagnosing axial spondyloarthritis

StudiesNo.Study populationGold standardSIJ/spineMRI lesionSESP+LR−LR
Longitudinal/RCT
 Bennett et al1950SpAX-raySIJGrade 3 SI+HLAB27 27B270.620.927.70.41
 Marzo-Ortega et al2076IBP (NSBP, HC)Clinical diagnosisSIJGrade 1 SI0.820.431.40.41
Grade 2 SI0.731.00.73
 Oostveen et al2125IBPX-raySIJGrade ≥2 SI0.850.471.60.31
Cross-sectional/case-control
 Weber et al22 23187AS, IBP (NSBP, HC)Clinical  diagnosisSIJBME (AS)0.90.9744.60.92
BME (IBP)0.510.97260.50
BME+ERO0.810.97270.19
 Weber et al24 25157AS, IBP (NSBP, HC)Clinical  diagnosisSIJBME0.730.97.30.3
BME and/or ERO0.820.98.20.2
FI0.210.978.30.81
FI with BME or ERO0.240.979.20.78
 Heuft-Dorenbosch et al2768IBPX-raySIJchronic changes0.490.9716.30.52
 Weber et al3095AS, IBP, (HC)Clinical  diagnosisSpine>2 CIL (AS)0.690.94120.32
>2 CIL (IBP)0.320.9680.70
LIL0.970.311.40.09
 Kim et al31104AS (HC)Clinical  diagnosisSpineMRI corner sign0.440.96110.58
Retrospective
 Wick et al26179AS (various)Clinical  diagnosisSIJERO0.110.931.570.95
BME0.350.781.590.83
 Bennett et al28 29185SpA (DA, IBP, HC)Clinical  diagnosisSIJ and spine>3 RLs0.330.9712.40.69
Posterior BME lesion0.130.9914.50.87
≥5 FRLs0.220.9812.60.79
  • The terms of the individual original publications have been used in the table.

  • AS, ankylosing spondylitis; BME, bone marrow oedema; CIL, corner inflammatory lesion; DA, degenerative arthropathy; ERO, erosion; FI, fatty infiltration; FRL, ‘fatty Romanus’ lesion; HC, healthy control; HLA27, human leucocyte antigen B27; IBP, inflammatory back pain; LIL, lateral segment inflammatory lesion; +LR, positive likelihood ratio; –LR, negative likelihood ratio; No., number of individuals included in the study; NSBP, non-specific back pain; RCT, randomised controlled trial; RL, ‘Romanus’ lesion; SE, sensitivity; SP, specificity; SI, sacroiliitis, SIJ, sacroiliac joints; SpA, spondyloarthritis.